Coagulation factor XIII (FXIII) is converted by thrombin and Ca 2 + into an active transglutaminase (FXIIIa) in the fi nal phase of coagulation cascade. Its main function is the mechanical stabilization of fi brin clot and its protection from fi brinolysis by cross-linking of fi brin chains and α 2 -plasmin inhibitor to fi brin. In non-substituted patients FXIII defi ciency is a severe hemorrhagic diathesis, not infrequently with fatal consequences. The main reason for using FXIII assays is the diagnosis of FXIII defi ciency. The aim of this review is to provide a comprehensive critical evaluation of the methods reported for the determination of FXIII activity in the plasma. Such methods are based on two principles: 1) measurement of labeled amines incorporated by FXIIIa into a glutamine residue of a substrate protein, 2) monitoring ammonia released from a peptide bound glutamine residue by FXIIIa using NAD(P)H dependent glutamate dehydrogenase indicator reaction. The incorporation assays are sensitive, but cumbersome and time-consuming, they are diffi cult to standardize and cannot be automated. The ammonia release assays are less sensitive, but quick, well standardized, and can be automated; this type of assay is recommended for the screening of FXIII defi ciency. The traditional clot solubility assay should not be used for this purpose.
Introduction
Coagulation factor XIII (FXIII) is a zymogen of tetrameric structure (FXIII-A 2 B 2 ) that consists of two catalytic A subunits (FXIII-A) and two carrier/inhibitory B subunits (FXIII-B). FXIII-A is synthesized by cells of bone marrow origin, while FXIII-B is produced by hepatocytes. The two subunits form complex in the plasma. FXIII-B is in excess and approximately 50 % of it exists in free non-complexed form. FXIII circulates in association with fi brinogen. FXIII is also present in platelets and monocytes/macrophages, however this cellular form is a dimer of FXIII-A (FXIII-A 2 ), which lacks FXIII-B. In plasma FXIII is activated by the concerted action of thrombin and Ca 2 + , fi rst thrombin cleaves off the activation peptide of 37 amino acids from the N-terminal end of FXIII-A, then in the presence of Ca 2 + FXIII-A and FXIII-B dissociate and the cleaved FXIII-A 2 assumes an enzymatically active confi guration. The presence of polymerized fi brin highly (80 to 100-fold) accelerates the activation process, and, if fi brin is present, the activation occurs on the surface of fi brin polymers. In cells, in the absence of FXIII-B, the elevation of Ca 2 + concentration is suffi cient to bring about the active confi guration. For more information on the structure and function of FXIII interested readers should consult most recent extensive reviews (1, 2) . Activated FXIII (FXIIIa) is a transglutaminase (proteinglutamine: amine γ -glutamyltransferase, EC 2.3.2.13) that catalyzes an acyl transfer reaction, in which the carboxamide group of a peptide/protein-bound glutamine residue is the acyl donor and an appropriate primary amine substrate is the acyl acceptor (3, 4) . Figure 1 demonstrates a simplifi ed scheme of the transglutaminase reaction. The reaction proceeds through an oxyanion intermediate (not shown on the Figure) , and ammonia is released as the acyl-enzyme intermediate, a thioesther between the peptide bound glutamine and the -SH group of the active-site cysteine of FXIIIa, is formed. Then, in the presence of a substrate primary amine, the acyl group is transferred to the acyl acceptor amine through a second oxyanion intermediate and the amine becomes covalently linked to the γ -glutamyl residue via a peptide ( " isopeptide " ) bond, and the active-site cysteine becomes deacylated. If the primary amine is the ε -amino group of a peptide/protein-bound lysine residue, the end-result is the cross-linking of two peptide chains. The measurement of released ammonia, (labeled) amine incorporated into a protein and the cross-linked product (see in red ellipses on Figure 1 ) all have been utilized for the measurement of FXIII activity.
The main physiological function of plasma FXIII is the cross-linking of fi brin γ -chains into dimers and α -chains into high molecular mass polymers. In addition it cross-links α 2 -plasmin inhibitor, the main physiological inhibitor of plasmin, to fi brin α -chain; fi rst a hetero-tetramer is formed, then, it becomes incorporated into α -chain polymers. This way the action of FXIIIa makes the fi brin network resistant to shear stress and protects it from prompt elimination by the powerful fi brinolytic enzyme, plasmin (2) .
There are two reasons why FXIII is determined in clinical practice and clinical research: 1) the diagnosis of FXIII defi ciencies and monitoring FXIII substitution of defi cient patients; 2) elevated FXIII level might represent a risk factor of thrombotic diseases in certain conditions. The latter is a topic of clinical research rather then routine diagnostics (5) .
Factor XIII defi ciencies
Inherited FXIII defi ciencies are classifi ed as FXIII-A and FXIII-B defi ciency. The former is a rare bleeding disorder, one diagnosed case in a population of two million. Its frequency might be ten times higher in populations in which consanguineous marriage is a common practice. It can be classifi ed as type I defi ciency, a quantitative defect due to the decreased synthesis of the protein, and type II defi ciency, which is characterized by normal or near normal concentration of FXIII-A with a functional defect. It is a very severe bleeding diathesis in the majority of patients not being on appropriate prophylactic treatment. Umbilical stump bleeding appears in 80 % of FXIII-A defi cient newborns, later in life intramuscular, subcutaneous, and unfortunately, also intracranial hemorrhage occur in a high percentage of patients with serious, occasionally fatal, (6) . In these cases the clinical symptoms were milder. Acquired defi ciency due to a neutralizing or non-neutralizing autoantibody against either of the FXIII subunits also results in severe, often life-threatening bleeding symptoms. It may accompany an autoimmune disease, most frequently systemic lupus erythematosus, or may also occur in the absence of any disease in elderly patients. Less severe acquired FXIII deficiencies may be due to consumption or decreased synthesis of FXIII subunits. In these cases the extent of decrease in plasma FXIII activity is moderate, rarely goes below 20 % . Most recent reviews provide detailed information on the clinical symptoms in FXIII defi ciencies and on the classifi cation of the disease (7 -9) .
The offi cial communication of the International Society on Thrombosis and Haemostasis, Scientifi c, and Standardization Committee (ISTH, SSC) recommends the following algorithm for the diagnosis and classifi cation of FXIII defi ciencies (7) :
A quantitative plasma FXIII activity assay is to be used (i) as " fi rst line " screening test (see later The supporting information to this communication provides further practical details in this matter. Table 1 indicates the generally reported FXIII values in different subclasses of FXIII defi ciencies as it was published in the offi cial ISTHSSC communication (7) .
Due to methodological problems (see later) no evidencebased data are available on the correlation between the severity of the disease and plasma FXIII activity. A further diffi culty is that FXIII defi ciency is one of the most unpredictable conditions among coagulation factor defi ciencies; in non-substituted patients life-threatening spontaneous bleeding might follow long non-symptomatic intervals. The values given below are only for orientation; individual patients may behave differently. It is generally accepted that severe bleeding diathesis occurs at FXIII level below 3 % of FXIII activity. Patients with plasma FXIII activity between 5 % and 30 % may bleed in hemostatic stress situations. The target pre-dose value in substituted patients is > 5 % FXIII activity. This is > 10 % during pregnancy and > 30 % during labor. During major surgery FXIII activity > 50 % is considered safe.
The effect of plasma FXIII level on the risk of thrombotic diseases
Earlier studies on association of the risk of coronary artery disease (CAD) and plasma FXIII levels included a relatively low number of male or predominantly male patients. The critical evaluation of these studies was recently published (5) . The results of these studies were inconclusive, which was partly due to methodological problems (interference by FXIII-A Val34Leu polymorphism, see later) and partly to not differentiating between the risk of coronary sclerosis without myocardial infarction and the risk of the acute event, i.e., myocardial infarction developed in atherosclerotic coronary vessels.
In a relatively large study involving 955 patients (377 females and 578 males) undergoing coronary angiography, participants were sub-grouped according to the presence or absence of signifi cant coronary sclerosis and according to the presence or absence of the history of myocardial infarction (10) . In females, but not in males, adjusted FXIII levels were moderately, but signifi cantly elevated in patients with the history of myocardial infarction. FXIII levels in the upper tertile represented a 2.5 to 3.0-fold risk of myocardial infarction only in females. Elevated FXIII level did not increase the risk of developing significant coronary sclerosis. Elevated FXIII level also exerted a similar gender-specifi c effect on the risk of peripheral artery disease (11) .
A recent review (12) enlists only two studies (13, 14) on the association of FXIII level with the risk of venous thromboembolism. Elevated FXIII-A levels did not infl uence the risk of venous thromboembolism in a recent nested case-control study involving 462 participants who developed venous thromboembolism and 1047 participants who remained free of it (14) . Further studies should explore if there is any gender or age specifi c difference. 
↓ ↓ ↓ , Highly decreased activity/concentration usually below 3 % , and in the majority of cases between non-detectable 1 % ; ↓ ↓ , considerably decreased activity/concentration usually 5 % -10 % ; ↓ , slightly decreased activity usually in the range of 20 % -70 % ; n, normal; na, non-applicable. The table indicates the generally reported abnormalities, exceptions may occur.
a Acquired FXIII defi ciencies due to increased consumption or decreased synthesis. The Table is reproduced from reference (7) with permission.
Functional FXIII assays
Clinical symptoms may indicate FXIII defi ciency, but the diagnosis is based on laboratory methods. The generally used screening tests for coagulopathies, prothrombin time, activated partial thromboplastin time and thrombin time are normal in FXIII defi ciency, unless there is another concomitant disorder in the clotting system. For instance, lupus anticoagulant with prolonged activated partial thromboplastin time may occur in SLE patients with autoantibodies against FXIII. Full evaluation of the clotting system should include a special test for the detection of FXIII defi ciency. The functional " fi rst line " screening assay is the key point in this respect. Due to traditional improper practice in screening, FXIII defi ciency is the most under-diagnosed bleeding diathesis.
In FXIII activity assays, FXIII is converted into an active transglutaminase by thrombin and Ca 2 + and, in all, except one assay, the products of transglutaminase activity are measured. Figure 1 demonstrates the three possible products that can be determined (see red ellipses), and, accordingly, the methods for the measurement of FXIII activity are based on three different principles: 1) the detection of fi brin cross-linking activity of FXIIIa (clot solubility tests and SDS PAGE analysis of fi brin cross-linking), 2) the determination of small molecular weight amine substrates covalently cross-linked to a protein substrate by FXIIIa (amine incorporation assays), 3) the measurement of ammonia released in the fi rst step of transglutaminase reaction (ammonia release assays). These assay principles and features of assays based on these principles are summarized in Table 2 . There is a single assay in which the isopeptidase activity of FXIIIa is measured. Qualitative/semiquantitative and quantitative functional FXIII assays will be discussed in detail.
Qualitative/semiquantitative FXIII assays based on fi brin cross-linking activity
Clot solubility assays Traditionally, a plasma clot soluble in concentrated urea solution or in dilute acids was considered as the sign of FXIII defi ciency. The clot solubility test goes back to the discovery of FXIII when a plasma protein activity that renders the clot insoluble in the presence of Ca 2 + was demonstrated (15 -17) . In the test used for diagnostic purposes plasma samples are clotted by adding thrombin and/or Ca 2 + and the clot is then suspended in 5 M or 8 M urea or in 2 % acetic acid or in 1% -5 % monochloroacetic acid. The method is not standardized, in different applications of the tests the inducers of clotting (thrombin and/or CaCl 2 ) and their concentrations, the time allowed for clotting, the type and concentration of the solvents, the time of the detection of solubility, etc. are all variables which infl uence the limit of detection of FXIII activity. In different reports the limit of detection varied from < 0.5 % to 5 % FXIII activity (18 -21) , i.e., depending on the test conditions, moderate and sometimes even severe FXIII defi ciencies cannot by detected by these poorly standardized qualitative tests. For these reasons, using the clot solubility tests a considerable part of FXIII defi ciencies remain undiagnosed, therefore its use as Sensitivity is relatively low. Plasma blank measurement is needed to compensate for FXIII-independent ammonia producing and NADH consuming reactions. Without compensation FXIII activity is overestimated, which is signifi cant in the low activity range.
Limit of quantitation is between 3 % and 10 % , depending on the assay type. In the case of a modifi ed assay it is approximately 1 % (Figure 3 ).
The limit of quantitation was not determined properly for most of the amine incorporation assays; the fi gure given in the (22) .
In summary, it has be emphasized, that, although a positive clot solubility test is strongly indicative of FXIII defi ciency, the possibility of defi ciency is in no way excluded by a negative test. Another drawback of clot solubility assays are that they cannot be used for monitoring prophylactic treatment and substitution therapy and they are also useless in moderate acquired defi ciencies.
Several attempts have been made to design an at least semiquantitative clot solubility assay. Such attempts included the use of FXIII-depleted fi brinogen as " substrate " with different plasma dilutions (23, 24) or the modifi cation of clot solubility assay by adding increasing amounts of FXIIIa inhibitors, such as iodoacetate (25) or antiserum specifi c to FXIII-A subunit (26) , to the undiluted plasma sample and determine the amount of inhibitor necessary to neutralize FXIIIa cross-linking activity. In a further modifi cation of the clot lysis assay (27) fi brinogen coated latex beads were exposed to thrombin. The beads aggregated as the consequence of interbead fi brin polymerization and in the absence of FXIII, the aggregates rapidly dissociated in 5 M urea. FXIII dose dependently inhibited the dissociation, which was quantifi ed by turbidimetry. These, in most cases poorly evaluated and standardized assays, did not gain popularity, partly because they are more cumbersome, time consuming and, in some cases, more expensive than commercially available rapid assays.
Fibrin clot analysis by SDS PAGE Fibrin cross-linking in plasma clot can be evaluated by SDS PAGE (28) . In this case plasma is clotted by thrombin and Ca 2 + , then the recovered fi brin clot is extensively washed to remove trapped, noncovalently attached proteins. The washed clot is dissolved in sample buffer and analyzed by SDS PAGE for γ -chain dimerization and α -chain cross-linking. As fi brin γ -chain dimerization is a highly sensitive function of FXIIIa, even traces (below 1 % ) of FXIII activity can be demonstrated by this qualitative or semi-quantitative test. Impaired fi brin crosslinking caused by fi brinogen abnormality can also detected by this test. The procedure is cumbersome and time-consuming and it is only used as a supplementary test in the diagnosis of FXIII defi ciency.
Quantitative FXIII assays
In all quantitative assays, FXIII is fi rst (or during the lag phase of the reaction) activated by thrombin and Ca 2 + . However, the transformation of fi brinogen into fi brin by thrombin causes diffi culties in the separation of free amines from proteinbound amines and fi brin would also interfere with photometric or fl uorimetric assays. The elimination of this problem has been solved in the following ways: 1) Traditionally, the denaturation of fi brinogen in plasma samples and detachment of FXIII from fi brinogen prior to the assays was achieved by a short heat treatment at 56 ° C in the presence of glycerol or ethyleneglycol (29) . It was expected that such a mild heat treatment separates FXIII from fi brinogen and leaves it intact. However, this was not quite the case and it was shown that a signifi cant unpredictable quantity of FXIII activity was lost during heat treatment (30) . A higher recovery of FXIII was achieved when fi brinogen was removed from the plasma by adsorption to bentonite (30, 31) . Bentonite treatment needed an extra step of centrifugation and now the elimination of fi brinogen by heat treatment and adsorption are only of historical interest; 2) The prevention of fi brin polymerization in the FXIII assay mixture by a polymerization inhibitory peptide was fi rst introduced by Miraglia and Greenberg (32) and later it became popular to include peptides, like GPRP or GPRPA, in the FXIII assay mixture (33 -35) ; 3) Finally, in highly sensitive amine incorporation assays the high dilution of plasma samples prevent the formation of fi brin polymers (36 -38) . It is to be noted that by eliminating fi brinogen and preventing fi brin polymerization, the FXIII activation accelerating effect of polymerized fi brin is lost and rather high thrombin concentration is needed to bring about full activation of FXIII.
Another A signifi cant step in the standardization of FXIII assays was the establishment of a WHO reference plasma by the FXIII Working Party of ISTH, SSC (43) . This plasma with assigned FXIII activity and plasma FXIII antigen values is available from the National Institute for Biological Standards and Control (Potters bar, UK) and it is to be used for the calibration of reference plasmas by companies producing FXIII assay kits.
Amine incorporation assays
The fi rst quantitative FXIII assays were based on the principle of amine incorporation. Table 3 enumerates the publications on such assays that were used for the determination of FXIII activity in human plasma. In these assays the covalent binding of an acyl acceptor substrate amine to an acyl donor glutamine residue of a protein by FXIIIa is measured. As discussed above the elimination of interfering fi brin formation was fi st solved by previous heat treatment of fi brinogen (29, 44, 46 -49) or by fi brinogen adsorption to bentonite (31) . More recently only fi brin polymerization inhibitory peptide (32, 35) and prevention of fi brin polymerization by high plasma dilution (35 -38) are used for this purpose. One of the burdens of amine incorporation assays is the separation of free non-bound amines from protein linked ones. This was fi rst solved by acid precipitation and removal of unbound amines by repeated washing of the protein precipitate (29, 32, 44, 45, 47, 48) . Later the separation was simplifi ed by the use of substrate proteins covalently or non-covalently bound to a surface (31, 35 -38, 46) . The disadvantage of this simplifi cation was that the substrate protein could not be used at saturating concentration, which impaired the precision of the assay.
Casein (29, 38, 44 -47, 49) , casein derivatives (31, 32, 48) and fi brinogen (35 -37) are the Gln donor substrate proteins used in various amine incorporation assays. Hammerstein casein is a mixture of different casein molecules. In addition to substrate Gln residues they also contain Lys residues, which are substrates for FXIIIa and these Lys residues compete with the amine substrates in the assay. Blocking the Lys residues by methylation or acetylation overcame this problem (31, 32, 48, 50) . Besides, there are a number of Gln residues in casein to which FXIIIa cross-links amines with different kinetics. A further problem was the gradual precipitation of substrate casein in the presence of Ca ions. Acetylated, dephosphorylated β -casein is exempt of these problems (50) , however it is not available commercially and its production is rather laborious. Fibrinogen, as opposed to fi brin, is a rather poor substrate of FXIIIa. However, the adsorption to a surface signifi cantly improves the substrate characteristics of fi brinogen.
Fluorescent dansylcadaverine (29, 49) , radiolabeled putrescine (32, 44 -47) , or biotinylated cadaverine (biotinamidopentylamine) (31, 35 -37) are the most frequently used amine substrates in FXIII assays. Putrescine is a diamine and it can provide two primary amine groups for the transglutaminase reaction, i.e., protein-linked putrescine still can offer its remaining free amine for cross-linking two protein molecules. This again, might infl uence the kinetics of the transglutaminase reaction. Although this is not a problem with other radiolabeled amine substrates, like glycine ethylesther or histamine, these amines have not been used in plasma FXIII assays.
Some of the assays use very long incubation times, up-to 4 h ( Table 3) . Activated FXIII is a rather instable enzyme and after 30 min gradually looses its activity at 37 ° C (unpublished observation). For this reason incubation longer than 30 min is not recommended. The measurement of incorporated fl uorescent or radiolabeled amines is straightforward. This is not the case with biotinylated cadaverine; in this case a separate detection reaction using streptavidin conjugated with a fl uorophore (35) or with an enzyme (31, 36, 37) is required. The detection using enzymatic (alkaline phosphates or β -galactosidase) reaction prolongs the assay time and it should be carefully controlled.
In general, the advantage of amine incorporation methods is their high sensitivity due to the use of fl uorescent, radiolabeled amines or the detection of the incorporated biotin moieties by an enzymatic reaction. The methods using dansyl-cadaverine can detect as low as 1 % plasma FXIII activity, while the sensitivity of the other methods goes even below that limit. However, the amine incorporation methods are rather troublesome and timeconsuming, to perform an assay takes long hours. They are diffi cult to standardize and the separation step makes it hardly possible to design a true kinetic assay. A pseudo-kinetic assay can be designed when the incorporation is determined at various times after the initiation of the reaction.
Ammonia release assays
The fi rst FXIII assay utilizing the measurement of ammonia released by FXIIIa from its Gln donor protein substrate was published in 1969 (51) . In this case ammonia formed in recalcifi ed clotted plasma was estimated. Further early methods determined ammonia formed in plasma or plasma supplemented with fi brinogen by ammonia selective electrode (52) or a modifi ed Berthelot reaction (53) . These end-point methods were impractical and required a high volume of plasma, they did not gain popularity.
A new principle was introduced by using glutamate dehydrogenase (GlDH) indicator reaction for monitoring the production of ammonia (30) . This principle made it possible to design the fi rst true kinetic FXIII assay (30) . In the assay, fi brinogen was removed by bentonite treatment. FXIII was activated by thrombin and Ca 2 + during the lag phase of the reaction. FXIIIa cross-linked the amine substrate (ethylamine) to the single substrate Gln residue in acetylated dephosphorylated β -casein and ammonia was released. The ammonia release was continuously monitored by glutamate dehydrogenase-mediated indicator reaction, in which NADPH became converted into NADP and the decrease in absorbance at 340 nm was measured.
The above principle was used in the development of two kinetic ammonia release FXIII assays (Figure 2) (33, 34) . In the new modifi ed assays fi brin formation was prevented by peptides that inhibited fi brin polymerization, the protein substrate was replaced by Gln containing oligopeptides and glycine ethylesther was used as amine substrate (Table 4 ) . Both modifi ed assays are now commercially available as Berichrom FXIII (Siemens, Marburg, Germany), REA-chrom FXIII (Reanal-ker, Budapest, Hungary) and TECHNOCHROM FXIII (Technoclone, Vienna, Austria) tests. These ammonia release assays are quick (only 10 min), one-step, true kinetic tests with good reproducibility and can be easily automated. Neither assay is infl uenced by the FXIII-A Val34Leu polymorphism (33, 34, 54) . They are widely used as screening tests for FXIII defi ciency. The Berichrom and TECHNOCHROM assays are compared in Table 4 (the Rea-chrom assay is identical with the TECHNOCHROM assay). The two kits use different Gln containing substrate Table 3 Characteristics of amine incorporation factor XIII activity assays. 1 h The reaction was terminated by EDTA.
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oligopeptides; in the Berichrom assay the decapeptide possesses an amino acid sequence similar to that of β -casein around the substrate Gln residue, the sequence of the dodecapeptide used in the TECHNOCHROM (and Rea-chrom) kit is identical with the N-terminal sequence of N1-isoform of α 2 -plasmin inhibitor.
In the indicator reaction NADH and NADPH are used in the Berichrom and TECHNOCHROM assays, respectively.
One of the problems to be discussed concerning the ammonia release FXIII assays comes from the ammonia producing and NADH consuming reactions in the plasma that result in decreased absorbance at 340 nm independently of FXIIIa activity. Lactate dehydrogenase present in the plasma is a major source of the NADH consuming side-reaction. The LDH substrate, pyruvate, is also present in the plasma, and its transformation to lactate directly consumes NADH, but not NADPH (55) . FXIIIa-independent ammonia production in the plasma samples is another source of non-specifi c NAD(P)H consumption (56, 57) . An example for such a reaction is the production of ammonia by the de-amidation of glutamine by γ -glutamyl transferase present in the plasma. The extent of these side-reactions varies individually and, if not subtracted, results in overestimation of FXIII activity (58) . Such an overestimation adds 2 % -15 % to plasma FXIII activity, which does not seem to cause clinically signifi cant problem around the normal range, however in FXIII deficient patients gives false information on the severity of FXIII defi ciency and on the effi ciency of replacement therapy (9, 34, 54, 58) . The overestimation of FXIII activity in the low activity range by the Berichrom FXIII assay was also demonstrated by surveys of the ECAT external quality assessment program (59) . To avoid the overestimation of FXIII activity the subtraction of a plasma blank, in which FXIIIa is inhibited by 1 mM iodoacetamide, is recommended (34, 54, 58) . A reagent for plasma blank measurement is included in the REA-chrom and TECHNOCHROM kits; in the Berichrom assay, plasma blank reagent is to be prepared by the user.
The disadvantage of the above assays is their relatively low sensitivity. In our hands, their limit of quantitation varied 3 % -10 % depending on the instruments used for FXIII activity determination. Unfortunately, this range is important The assay was based on the method described by Kohler et al. (42) . (Table 3 Fibrin polymerization inhibitory peptide G-P-R-P-A G-P-R-P FXIII activator Thrombin + Ca The amino acid sequence of the peptide in the Berichrom kit corresponds, with some modifi cation, to the sequence of β -casein around the substrate Gln residue. The sequence of the dodecapeptide in the TECHNOCHROM kit corresponds to the N-terminal sequence of the FXIIIa substrate α 2 -plasmin inhibitor isoform (N1 α 2 -plasmin inhibitor) (42) . GlDH, glutamate dehydrogenase.
for the stratifi cation of disease severity and for controlling the replacement therapy. With a slight modifi cation of the TECHNOCHROM assay, doubling the sample volume and extending the measuring interval after the 5 min lag period from 5 to 10 min, we were able to measure FXIII activity below 5 % with good linearity and acceptable repeatability ( Figure 3 ). The modifi ed assay satisfi es most of the requirements of clinical diagnostics and monitoring replacement therapy. If an even more sensitive assay is needed, e.g., for studies of phenotypegenotype correlation in the very low activity range, one of the amine incorporation assays is recommended. Kappel et al. modifi ed the Berichrom FXIII assay (60) by replacing NADH for thio-NADH in the indicator reaction, this way the measuring wavelength was brought into the visible range (405 nm) commonly available on coagulometers with optical channel. The change of the cofactor however does not eliminate the problem caused by NADH consuming and ammonia producing side reactions (see above) and the modifi cation did not improve the sensitivity of the assay (59) .
FXIII assay based on the determination of isopeptidase activity An interesting concept for the determination of FXIII activity was put forward by Parameswaran et al. (61) . It was shown that in certain conditions FXIIIa can exert isopeptidase activity, i.e., as opposed to its cross-linking activity, it can release primary amines bound to a Gln residue in an oligopeptide. They used a primary amine labeled with a quencher, and a peptide substrate that contained a fl uorophore. Gradual removal of the quencher containing amine by FXIIIa resulted in increasing fl uorescence. This assay was modifi ed and made more sensitive by Oertel et al. (62) . They used 2-aminobenzoyl fl uorophore labeling at the N-terminus of the peptide corresponding to the N-terminal amino acid sequence of α 2 -plasmin inhibitor and dinitrophenyl cadaverine as internal quencher. Fluorescence was measured at 418 nm (excitation at 313 nm). The reagent is commercially available for research use from Zedira (Darmstadt, Germany). The limit of quantitation (5 % FXIII activity) of the fl uorimetric assay does not compare favorably to that of the widely used photometric ammonia release assays. Its correlation with the FXIII-A subunit ELISA was poorer than that of the photometric assay and the correlation with the photometric transglutaminase assay was not very good, either (62) . It remains to be seen to what extent the measured isopeptidase activity refl ects the physiologically important cross-linking activity of FXIIIa.
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